erectile

Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.

Phentolamine mesylate (Phentolamine methanesulfonate) is a nonselective alpha-adrenergic antagonist used to treat hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of [RAYNAUD DISEASE] and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.

Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes

Vardenafil dihydrochloride (Levitra) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.

NS309 is a nonselective activator of small- and intermediate-conductance Ca2+-activated K+ (SK/KCa2 and IK/KCa3.1) channels (EC50s range from 0.12-1.2 µM for SK channels and 10-90 nM for IK channels). It can also activate voltage-gated Kv11.1 channels (hE

THIQ is a selective melanocortin-4 receptor (MC4R) agonist (hMC4R and rMC4R with IC50 of 1.2 nM and 0.6 nM , respectively).

Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction.

Mirodenafil is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.

Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist

Mirodenafil dihydrochloride is a PDE-5 inhibitor developed for the treatment of erectile dysfunction.

Hydroxythiohomosildenafil (Sulfohydroxyhomo sildenafil) is a sildenafil analog that may be used to study erectile dysfunction.

Dasantafil (SCH446132) is a small molecule phosphodiesterase-5A (PDE5A) inhibitor used to treat genitourinary disorders and study erectile dysfunction.

Sildenafil citrate (UK-92480 citrate) , a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) Inhibitor, is used extensively for erectile dysfunction and less commonly for pulmonary hypertension.

Yohimbine hydrochloride is a plant-derived alkaloid with alpha-2 adrenergic receptor blocking activity. By blocking presynaptic or postsynaptic alpha-2 adrenergic receptors, it promotes the release of norepinephrine and dopamine. It has been used in studies related to mydriasis and erectile dysfunction and is commonly used to induce hypertension models.

Nortadalafil (Demethyl Tadalafil) is demethyl Tadalafil, which is a PDE5 inhibitor, treating erectile dysfunction (ED) ; and under the name Adcirca for the treatment of pulmonary arterial hypertensio.

Bivamelagon hydrochloride is a selective MC4R agonist (EC50=36.5 nM, Ki=65 nM) with the advantages of oral available and blood-brain barrier penetration, suitable for obesity and diabetes research.

Prostaglandin E1 (Alprostadil) is the naturally occurring prostaglandin E1 (PGE1) which displays a variety of pharmacologic actions. Prostaglandin E1 is a potent vasodilator agent that increases peripheral blood flow, inhibits platelet aggregation, and induces bronchodilation. Used in the treatment of erectile dysfunction, this agent produces corporal smooth muscle relaxation by binding to PGE receptors, resulting in the activation of adenylate cyclase and the subsequent accumulation of 3'5'-cAMP.

Lunamarine, a PDE5 inhibitor with BBB permeability, is utilized in research for pulmonary arterial hypertension (PAH) and erectile dysfunction (ED).

BMS-341400 mesylate (Compound 6) is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM and is useful in the study of erectile dysfunction.

Xanthoanthrafil is a potent inhibitor of phosphodiesterase-5 (PDE5) with an IC50 of 3.95 ng/mL. It is utilized in the study of erectile dysfunction.

Acetylvardenafil is a novel analogue of Vardenafil where the sulfonyl group is replaced by an acetyl group. As a PDE-5 inhibitor, Acetylvardenafil is utilized in the research of erectile dysfunction (ED).

PDE5-IN-15 (compound 21) is a xanthine derivative and PDE5 inhibitor with IC50 values of 0.002 μM for hPDE5, 0.180 μM for bPDE6, 2.85 μM for bPDE1, and 2.22 μM for hPDE3. It exhibits good oral bioavailability in dogs and is applicable in research related to male erectile dysfunction.

T-1032 is a selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 1.0 nM. It induces relaxation in isolated rabbit corpus cavernosum and is applicable in the study of erectile dysfunction.